NPM1 and leukemia: Moreover, the detected high number of additional aberrations accompanying RUNX1 mutation and the observed overlap with the AML-causing events CBF-fusions or NPM1 mutation in the assessed paediatric patients, further support the concept that RUNX1 mutations are more likely to contribute to the late-stage leukaemia development.